Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and aflibercept or placebo in patients with mCRC that progressed on prior oxaliplatin treatment.
Paul Ruff
Honoraria - Amgen; Merck KGaA; Roche
Research Funding - Amgen; Sanofi
Other Remuneration - Amgen
Radek Lakomy
Research Funding - Sanofi
Jana Prausová
No relevant relationships to disclose
Guy Van Hazel
No relevant relationships to disclose
Vladimir Mikhailovich Moiseyenko
No relevant relationships to disclose
Pankaj Bhargava
Employment or Leadership Position - Sanofi
Josep Tabernero
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; Merck KGaA; Millennium; Novartis; Onyx
Honoraria - Amgen; Merck KGaA; Novo Nordisk; Roche; Sanofi
Eric Van Cutsem
Research Funding - Sanofi